Cyclic GMP modulators on vascular adrenergic neurotransmission

Area of Science:

• Pharmacology
• Vascular Biology
• Neurotransmission

Background:

• The endothelium plays a crucial role in regulating vascular tone.
• Adrenergic neurotransmission involves complex interactions between nerves and smooth muscle.
• The role of cyclic GMP (cGMP) in endothelium-dependent vascular responses requires further elucidation.

Purpose of the Study:

• To investigate the influence of the endothelium on rabbit carotid artery sensitivity to various adrenergic agonists.
• To explore the role of cyclic GMP (cGMP) in mediating endothelium-dependent vascular responses.
• To determine the contribution of endothelial alpha-adrenoceptors to vascular regulation.

Main Methods:

• Isolated rabbit carotid artery rings with and without endothelium were used.
• Vascular contractions were measured in response to electrical stimulation, tyramine, norepinephrine, phenylephrine, and UK 14304.
• The effects of LY 83583 (cGMP-lowering agent) and M & B 22948 (cGMP phosphodiesterase inhibitor) were assessed.
• Pharmacological manipulation using yohimbine (alpha 2-antagonist) and prazosin (alpha 1-blocker) was performed.

Main Results:

• The endothelium significantly reduced artery sensitivity to norepinephrine, phenylephrine, and UK 14304.
• Endothelium-dependent depression of tone was abolished by LY 83583, restoring sensitivity.
• M & B 22948 inhibited agonist-induced contractions in intact arteries, suggesting cGMP involvement.
• Yohimbine increased UK 14304 contractions in intact arteries, indicating a minor role for endothelial alpha 2-adrenoceptors.

Conclusions:

• Intrinsic cyclic GMP levels, primarily via endothelium-derived relaxing factor, regulate adrenergic neurotransmission.
• Basal release of endothelium-derived relaxing factor and, to a lesser extent, endothelial alpha 2-adrenoceptor activation contribute to this regulation.
• Altering cGMP levels does not significantly impact prejunctional norepinephrine release.